Literature DB >> 16251213

Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study.

Rutger Goekoop1, Philip Scheltens, Frederik Barkhof, Serge A R B Rombouts.   

Abstract

Pharmacological functional MRI (phMRI) examines the impact of pharmacologically induced neurochemical changes on brain function at a system level. The current phMRI study directly compared effects of cholinergic stimulation on brain function between patients with Alzheimer's disease and mild cognitive impairment, a disease stage preceding the development of Alzheimer's disease. Brain function during recognition of (un)familiar information was examined for changes after exposure to galantamine, a cholinesterase inhibitor used for treating memory deficits in Alzheimer's disease. Alzheimer patients [n = 18; age 74.5 years +/- 8.2; Mini-Mental State Examination (MMSE) 22.5 +/- 2.4] and patients with mild cognitive impairment (n = 28; mean age 73.6 +/- 7.5; MMSE 27.0 +/- 1.2) were scanned during face recognition under three different conditions: at baseline, and after acute (single dose) and prolonged exposure (5 days) to galantamine. Functional data were analysed in an event-related fashion. In both groups, acute exposure produced strong increases in brain activation (Z > 3.1). Prolonged exposure produced less strong effects that mainly involved decreases in activation (Z > 3.1). In mild cognitive impairment, acute exposure increased activation in posterior cingulate, left inferior parietal, and anterior temporal lobe. Prolonged exposure decreased activation in similar posterior cingulate areas, and in bilateral prefrontal areas. Effects were stronger for positive ('familiar') than for negative ('unfamiliar') decisions, indicating that the effect was specific to memory retrieval. In Alzheimer patients, acute exposure increased activation bilaterally in hippocampal areas, whereas prolonged exposure decreased activation in these areas. Effects were more pronounced for negative than for positive decisions, suggesting a preferential effect on memory encoding. Unique profiles of signal reactivity were found in a number of areas, including left inferior parietal lobe and left hippocampus proper. The reactivity of posterior cingulate and hippocampal structures to cholinergic challenge suggests a key role of the cholinergic system in the functional processes that lead to Alzheimer's disease. The differential response to cholinergic challenge in mild cognitive impairment and Alzheimer patients may reflect a difference in the functional status of the cholinergic system between both groups, which is in line with recent results showing a differential clinical response to cholinergic treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16251213     DOI: 10.1093/brain/awh671

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  34 in total

Review 1.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

Authors:  Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

Review 2.  Cholinergic modulation of cognition: insights from human pharmacological functional neuroimaging.

Authors:  Paul Bentley; Jon Driver; Raymond J Dolan
Journal:  Prog Neurobiol       Date:  2011-06-17       Impact factor: 11.685

Review 3.  Hippocampal plasticity during the progression of Alzheimer's disease.

Authors:  E J Mufson; L Mahady; D Waters; S E Counts; S E Perez; S T DeKosky; S D Ginsberg; M D Ikonomovic; S W Scheff; L I Binder
Journal:  Neuroscience       Date:  2015-03-12       Impact factor: 3.590

4.  Cholinergic Grb2-Associated-Binding Protein 1 Regulates Cognitive Function.

Authors:  Nan-Nan Lu; Chao Tan; Ning-He Sun; Ling-Xiao Shao; Xiu-Xiu Liu; Yin-Ping Gao; Rong-Rong Tao; Quan Jiang; Cheng-Kun Wang; Ji-Yun Huang; Kui Zhao; Guang-Fa Wang; Zhi-Rong Liu; Kohji Fukunaga; Ying-Mei Lu; Feng Han
Journal:  Cereb Cortex       Date:  2018-07-01       Impact factor: 5.357

Review 5.  The senescence hypothesis of disease progression in Alzheimer disease: an integrated matrix of disease pathways for FAD and SAD.

Authors:  Sally Hunter; Thomas Arendt; Carol Brayne
Journal:  Mol Neurobiol       Date:  2013-04-03       Impact factor: 5.590

Review 6.  The significance of the cholinergic system in the brain during aging and in Alzheimer's disease.

Authors:  R Schliebs; T Arendt
Journal:  J Neural Transm (Vienna)       Date:  2006-10-13       Impact factor: 3.575

7.  Muscarinic and Nicotinic Modulation of Memory but not Verbal Problem-solving.

Authors:  Shawn F Smyth; David Q Beversdorf
Journal:  Cogn Behav Neurol       Date:  2019-12       Impact factor: 1.600

8.  Cholinergic enhancement of functional networks in older adults with mild cognitive impairment.

Authors:  Judy Pa; Anne S Berry; Mariana Compagnone; Jacqueline Boccanfuso; Ian Greenhouse; Michael T Rubens; Julene K Johnson; Adam Gazzaley
Journal:  Ann Neurol       Date:  2013-06-17       Impact factor: 10.422

9.  Test-retest reliability of fMRI verbal episodic memory paradigms in healthy older adults and in persons with mild cognitive impairment.

Authors:  Francis Clément; Sylvie Belleville
Journal:  Hum Brain Mapp       Date:  2009-12       Impact factor: 5.038

Review 10.  Advances in functional magnetic resonance imaging: technology and clinical applications.

Authors:  Bradford C Dickerson
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.